#USA #New York #Class Action #Bronstein Gewirtz #Actinium Pharmaceuticals

Class Action Alert: Actinium Pharmaceuticals Investors

Overview

On April 9, 2025, the law firm Bronstein, Gewirtz & Grossman LLC announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. This legal move comes after many investors experienced significant financial losses due to alleged misrepresentations and misleading statements made by the company regarding its drug development and FDA approval processes.

Background

The class action targets all individuals and entities who purchased Actinium securities between March 31, 2022, and August 2, 2024. It highlights a critical period during which the defendants purportedly made materially false statements, leading investors to believe there was a high likelihood of approval for Actinium's Biologics License Application for its drug Iomab-B. The complaint specifically points out the inconsistent results from the Phase 3 Sierra trial conducted by the company. While the trial reported positive outcomes concerning complete remission data, it failed to demonstrate statistically significant or clinically meaningful overall survival rates, which raised concerns about the drug's efficacy and approval potential by the FDA.

Allegations

According to the allegations, Actinium's executives misled investors by downplaying the significance of the Sierra trial's poor overall survival data and incorrectly asserting that the FDA had endorsed the trial's design. This misinformation not only affected the company’s stock price but also resulted in substantial financial damages for those who invested during this misleading phase.

While optimism surrounding clinical trials can often drive stock prices higher, the revelations about misrepresentation have been detrimental. Investors are now looking for justice and recovery through this lawsuit.

Taking Action

Investors who think they were affected by the actions of Actinium Pharmaceuticals are encouraged to visit the law firm’s website at bgandg.com/ATNM for more information. Those potentially eligible to join this class action must act before May 26, 2025, when the deadline to request lead plaintiff status approaches. Importantly, participation does not require any upfront fees—they operate on a contingency basis, meaning legal costs will only be covered if the case results in a recovery.

Why Join the Action?

Bronstein, Gewirtz & Grossman LLC is renowned for its expertise in securities fraud and investor protection cases. The firm boasts a strong track record, having managed to recover hundreds of millions of dollars for investors nationwide. Joining this lawsuit not only assists in seeking restitution for personal losses but also raises awareness of corporate responsibility in financial communications.

Conclusion

The ongoing class action presents a critical opportunity for investors who believe they have been wronged by the actions of Actinium Pharmaceuticals. Their voices can contribute to holding the company accountable and potentially reclaiming their investments lost during the tumultuous class period. Prospective plaintiffs should not hesitate to take action, as this could be a pivotal moment in seeking justice. Keep updated with further developments through the law firm’s social media platforms and website.

For more details, please contact:
Peretz Bronstein, Esq.
Nathan Miller, Client Relations Manager
Bronstein, Gewirtz & Grossman, LLC
Phone: 332-239-2660
Email: contact@bgandg.com

Stay vigilant and informed; the financial landscape is constantly evolving, and protecting investor interests is paramount.